Walleye Capital LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 72,009 shares of the specialty pharmaceutical company's stock, valued at approximately $3,981,000. Walleye Capital LLC owned about 0.34% of ANI Pharmaceuticals at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ANIP. XTX Topco Ltd purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $997,000. Barclays PLC grew its position in ANI Pharmaceuticals by 9.8% during the 4th quarter. Barclays PLC now owns 157,060 shares of the specialty pharmaceutical company's stock worth $8,682,000 after acquiring an additional 14,027 shares during the last quarter. Raymond James Financial Inc. bought a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $3,916,000. Legal & General Group Plc boosted its position in ANI Pharmaceuticals by 5.6% during the 4th quarter. Legal & General Group Plc now owns 48,425 shares of the specialty pharmaceutical company's stock valued at $2,677,000 after buying an additional 2,585 shares during the period. Finally, Bank of Montreal Can increased its position in shares of ANI Pharmaceuticals by 3.7% in the fourth quarter. Bank of Montreal Can now owns 230,153 shares of the specialty pharmaceutical company's stock valued at $12,723,000 after acquiring an additional 8,257 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.
ANI Pharmaceuticals Trading Up 1.6 %
Shares of NASDAQ:ANIP traded up $1.08 during trading hours on Tuesday, hitting $69.08. 25,502 shares of the company's stock traded hands, compared to its average volume of 270,172. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.48. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market capitalization of $1.50 billion, a P/E ratio of -124.86 and a beta of 0.49. The business has a fifty day moving average price of $63.43 and a 200-day moving average price of $59.53.
Insider Activity at ANI Pharmaceuticals
In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,200 shares of company stock worth $197,792. Company insiders own 12.70% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ANIP. StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, April 16th. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday. Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $80.13.
Get Our Latest Analysis on ANIP
ANI Pharmaceuticals Company Profile
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
